Full Text View
Tabular View
No Study Results Posted
Related Studies
SYMBICORT® in the Treatment of COPD (SRP COPD)
This study has been completed.
First Received: November 26, 2007   Last Updated: April 3, 2009   History of Changes
Sponsor: AstraZeneca
Information provided by: AstraZeneca
ClinicalTrials.gov Identifier: NCT00564499
  Purpose

A Scientific Research Program to evaluate the efficacy of SYMBICORT® 320/9μg in the treatment of COPD in real life environment by General Practitioners


Condition
COPD

Study Type: Observational
Study Design: Case-Crossover, Prospective
Official Title: A Scientific Research Program to Evaluate the Efficacy of SYMBICORT® 320/9μg in the Treatment of COPD in Real Life Environment by General Practitioners

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Study Start Date: March 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients (m/f) with COPD (GOLD stadium III and IV)

Exclusion Criteria:

  • patients who recently quit smoking (<3months)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00564499

Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: E Louis, PR Université Libre de Liège
  More Information

No publications provided

Study ID Numbers: SRP-RB-COPD-2005/1
Study First Received: November 26, 2007
Last Updated: April 3, 2009
ClinicalTrials.gov Identifier: NCT00564499     History of Changes
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products

Keywords provided by AstraZeneca:
COPD
Symbicort
General Practitioners

Additional relevant MeSH terms:
Respiratory System Agents
Lung Diseases, Obstructive
Symbicort
Respiratory Tract Diseases
Therapeutic Uses
Lung Diseases
Anti-Asthmatic Agents
Pharmacologic Actions
Pulmonary Disease, Chronic Obstructive

ClinicalTrials.gov processed this record on February 08, 2010